MX2023012971A - Agonistas del receptor de orexina y sus usos. - Google Patents
Agonistas del receptor de orexina y sus usos.Info
- Publication number
- MX2023012971A MX2023012971A MX2023012971A MX2023012971A MX2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A MX 2023012971 A MX2023012971 A MX 2023012971A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- receptor agonists
- orexin receptor
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163183321P | 2021-05-03 | 2021-05-03 | |
| PCT/EP2022/061851 WO2022233872A1 (en) | 2021-05-03 | 2022-05-03 | Orexin receptor agonists and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012971A true MX2023012971A (es) | 2024-01-16 |
Family
ID=81940742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012971A MX2023012971A (es) | 2021-05-03 | 2022-05-03 | Agonistas del receptor de orexina y sus usos. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240254143A1 (enExample) |
| EP (1) | EP4334323A1 (enExample) |
| JP (1) | JP2024516033A (enExample) |
| KR (1) | KR20240004802A (enExample) |
| CN (1) | CN117616030B (enExample) |
| AU (1) | AU2022269811A1 (enExample) |
| BR (1) | BR112023022050A2 (enExample) |
| CA (1) | CA3217403A1 (enExample) |
| IL (1) | IL308099A (enExample) |
| MX (1) | MX2023012971A (enExample) |
| TW (1) | TW202309051A (enExample) |
| WO (1) | WO2022233872A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| US20240425519A1 (en) * | 2021-11-04 | 2024-12-26 | University Of Washington | Novel spirocyclic compounds as klhdc2 ligands |
| JP2026506356A (ja) | 2023-01-31 | 2026-02-24 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 大環状オレキシン受容体アゴニスト及びその使用 |
| CN116478076A (zh) * | 2023-04-26 | 2023-07-25 | 南京优氟医药科技有限公司 | 一种(2s,4s)-1-叔丁氧羰基-2-(二氟甲基)-4-羟基吡咯烷的制备方法 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0687268B1 (en) * | 1993-03-04 | 1998-05-27 | Pfizer Inc. | Spiroazacyclic derivatives as substance p antagonists |
| EP0997464B1 (en) * | 1998-10-23 | 2005-02-16 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists |
| US8530648B2 (en) * | 2009-12-21 | 2013-09-10 | Novartis Ag | Diaza-spiro[5.5]undecanes |
| US20120101110A1 (en) * | 2010-10-26 | 2012-04-26 | Sangamesh Badiger | Diaza-spiro[5.5]undecanes |
| SG11201806429PA (en) * | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| US11655241B2 (en) * | 2018-06-29 | 2023-05-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| US11098029B2 (en) * | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
-
2022
- 2022-05-03 MX MX2023012971A patent/MX2023012971A/es unknown
- 2022-05-03 WO PCT/EP2022/061851 patent/WO2022233872A1/en not_active Ceased
- 2022-05-03 KR KR1020237041381A patent/KR20240004802A/ko active Pending
- 2022-05-03 JP JP2023567888A patent/JP2024516033A/ja active Pending
- 2022-05-03 CA CA3217403A patent/CA3217403A1/en active Pending
- 2022-05-03 TW TW111116714A patent/TW202309051A/zh unknown
- 2022-05-03 IL IL308099A patent/IL308099A/en unknown
- 2022-05-03 AU AU2022269811A patent/AU2022269811A1/en active Pending
- 2022-05-03 EP EP22727800.9A patent/EP4334323A1/en active Pending
- 2022-05-03 BR BR112023022050A patent/BR112023022050A2/pt unknown
- 2022-05-03 CN CN202280045968.9A patent/CN117616030B/zh active Active
- 2022-05-03 US US18/558,245 patent/US20240254143A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022233872A1 (en) | 2022-11-10 |
| EP4334323A1 (en) | 2024-03-13 |
| CA3217403A1 (en) | 2022-11-10 |
| TW202309051A (zh) | 2023-03-01 |
| CN117616030B (zh) | 2026-06-19 |
| CN117616030A (zh) | 2024-02-27 |
| KR20240004802A (ko) | 2024-01-11 |
| IL308099A (en) | 2023-12-01 |
| JP2024516033A (ja) | 2024-04-11 |
| AU2022269811A1 (en) | 2023-11-16 |
| US20240254143A1 (en) | 2024-08-01 |
| BR112023022050A2 (pt) | 2023-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023015074A (es) | Agonistas de sulfonamidas del receptor de orexina y sus usos. | |
| EP4458834A3 (en) | Heterocyclic glp-1 agonists | |
| EP4699609A3 (en) | Heterocyclic glp-1 agonists | |
| MX2023014630A (es) | Activadores de dimetoxifenilalquilamina de receptores de serotonina. | |
| MX2023001311A (es) | Agonistas heterociclicos de glp-1. | |
| MX2025015186A (es) | Inhibidores de pi3k y uso de estos | |
| MX2022010011A (es) | Inhibidores de prmt5 novedosos. | |
| MX2025004220A (es) | Compuestos triciclicos y sus usos | |
| MX2021000887A (es) | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. | |
| MX2020000268A (es) | Agonista de fxr. | |
| PH12021551256A1 (en) | Pantetheine derivatives and uses thereof | |
| IS8502A (is) | Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar | |
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| BR112023022050A2 (pt) | Agonistas do receptor de orexina e usos destes | |
| MX2025010256A (es) | Derivados de hidroquinazolina para el tratamiento de una enfermedad o un trastorno | |
| MX2025005223A (es) | Agonistas del estimulador de genes de interferon (sting) | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| MX2024002409A (es) | Terapias contra el cancer. | |
| MX2023009954A (es) | Compuestos de aminopirimidina y métodos de uso de estos. | |
| MX2024014790A (es) | Agonistas del receptor macrocíclico de orexina y sus usos | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| CR20230218A (es) | Nuevos derivados de indazol acetileno | |
| MX2021003508A (es) | Derivados de 5-azaindazol como antagonistas del receptor de adenosina. | |
| WO2022099060A3 (en) | Bicyclic pyridazinones as thyroid hormone receptor beta (tr-beta) agonists | |
| GEAP202516820A (en) | Prmt5-mta inhibitor |